Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results PR Newswire - Thu Jul 9, 3:01PM CDT

Conference Call and Webcast Scheduled for Thursday, July 30

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia PR Newswire - Wed Jul 1, 3:05PM CDT

SAN DIEGO , July 1, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont...

NBIX : 170.88 (-0.39%)
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period PR Newswire - Mon Jun 15, 3:10PM CDT

SAN DIEGO , June 15, 2026 /PRNewswire/ -- Soleno Therapeutics , a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment...

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 PR Newswire - Mon Jun 15, 3:05PM CDT

SAN DIEGO , June 15, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients...

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PR Newswire - Mon Jun 15, 7:35AM CDT

SAN DIEGO , June 15, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst ® Pediatric study showing positive growth...

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients PR Newswire - Mon Jun 8, 3:05PM CDT

SAN DIEGO , June 8, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new post-hoc data from the KINECT ® 4 clinical trial demonstrating that adults with...

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities PR Newswire - Mon Jun 8, 7:30AM CDT

SAN DIEGO , June 8, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities...

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 PR Newswire - Wed Jun 3, 7:30AM CDT

SAN DIEGO , June 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to...

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June PR Newswire - Tue May 26, 3:01PM CDT

SAN DIEGO , May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:

NBIX : 170.88 (-0.39%)
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules PR Newswire - Mon May 18, 3:05PM CDT

SAN DIEGO , May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact...

NBIX : 170.88 (-0.39%)

Barchart Exclusives

AI Investors Are Becoming Pickier. 2 Stocks Still Stand Out. Barchart - Sat Jul 18, 12:30PM CDT
The easy gains from AI may be over, but few companies still stand to benefit from the next wave of AI infrastructure spending. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.